Revision as of 15:30, 10 February 2023 editOzzie10aaaa (talk | contribs)Autopatrolled, Extended confirmed users, New page reviewers213,612 editsm Cleaned up using AutoEd← Previous edit | Latest revision as of 16:44, 12 November 2023 edit undoEntranced98 (talk | contribs)Extended confirmed users, Pending changes reviewers, Rollbackers173,077 edits Importing Wikidata short description: "Chemical compound"Tag: Shortdesc helper | ||
Line 1: | Line 1: | ||
{{Short description|Chemical compound}} | |||
{{one source|date=August 2014}} | {{one source|date=August 2014}} | ||
{{Drugbox | {{Drugbox |
Latest revision as of 16:44, 12 November 2023
Chemical compoundThis article relies largely or entirely on a single source. Relevant discussion may be found on the talk page. Please help improve this article by introducing citations to additional sources. Find sources: "Troxacitabine" – news · newspapers · books · scholar · JSTOR (August 2014) |
Identifiers | |
---|---|
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C8H11N3O4 |
Molar mass | 213.193 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(what is this?) (verify) |
Troxacitabine (brand name Troxatyl) is a nucleoside analogue with anticancer activity. Its use is being studied in patients with refractory lymphoproliferative diseases.
References
- Vose JM, Panwalkar A, Belanger R, Coiffier B, Baccarani M, Gregory SA, et al. (January 2007). "A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma". Leukemia & Lymphoma. 48 (1): 39–45. doi:10.1080/10428190600909578. PMID 17325846. S2CID 36220728.
This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |